小脑的RTMS 使用加速刺激协议改善了帕金森病患者的步态
Marcus Grobe-Einsler1,2, Annemarie Lupa1, Johannes Weller1
1Department of Neurology, University Hospital Bonn, Bonn, Germany.
Neurorehabilitation and neural repair
|May 28, 2024
概括
重复性横磁刺激 (rTMS) 与多式疗法相结合,改善了帕金森病患者的运动功能. 这种加快的5天rTMS治疗是有效的,耐受性很好,表明其作为附加疗法的潜力.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 康复医学 康复医学 康复医学
背景情况:
- 重复性横磁刺激 (rTMS) 是一种非侵入性脑刺激技术,有效治疗帕金森病 (PD).
- 将rTMS与跑步机训练相结合,比单独跑步机训练更能改善PD的步态.
研究的目的:
- 为了评估一种新的高强度,短期干预的rTMS与帕金森病多模式综合治疗 (PD-MCT) 结合.
- 评估这种联合治疗对PD患者运动功能的影响.
主要方法:
- 一个随机的双盲假控制试验,涉及36名PD患者.
- rTMS (48 Hz) 或假刺激在小脑上每天施加三次连续5天,与PD-MCT一起.
- 主要结果:UPDRS运动分数;次要结果:定量运动任务. 在基线,治疗后和4周后的评估.
主要成果:
- 从基线到治疗后,rTMS组在UPDRS III分数 (-8.2分,P=.004) 中显著改善.
- 在这两组中,在8米步行测试或动态位图学中都没有观察到显著的变化.
- 加速5天rTMS协议是有效的,并且耐受良好.
结论:
- 压缩到5天的rTMS协议对PD有效且耐受良好.
- rTMS可以增加PD运动症状的多式综合治疗.
- 在帕金森病中治疗姿势不稳定时,rTMS似乎无效.
更多相关视频
07:20Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy
Published on: August 9, 2024
1.1K
08:58Use of a Foot-Induced Digitally Controlled Resistance Device for Functional Magnetic Resonance Imaging Evaluation in Patients with Foot Paresis
Published on: July 7, 2023
281
相关概念视频
01:24Parkinson's Disease: Treatment
261
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
261
01:15Parkinson's Disease: Overview
528
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
528